Real-world treatment attrition rates in advanced esophagogastric cancer

Table 2 Treatment details for patients who received at least two lines of systemic therapy

Second-line chemotherapy backbone [n = 123, n (%)]
5-FU/oxaliplatin	9 (7)
5-FU/irinotecan	21 (17)
5-FU/cisplatin	3 (2)
Ramucirumab/paclitaxel	76 (62)
Docetaxel	8 (7)
Capecitabine	2 (2)
Irinotecan	3 (2)
Trastuzumab alone	1 (1)
Best response to second-line treatment, n (%)
Complete response	2 (2)
Partial response	17 (14)
Stable disease	27 (22)
Progressive disease	73 (59)
Unknown	4 (3)
Median duration of second-line treatment (mo)	2.8 (1.4-5.7)
Reason for discontinuation of second-line treatment, n (%)
Progression	100 (81)
Toxicity	7 (6)
Other	12 (10)
Unknown	11 (9)
Third-line chemotherapy backbone [n = 40, n (%)]
5-FU	1 (2.5)
5-FU/irinotecan	14 (35)
5-FU/oxaliplatin	1 (2.5)
Docetaxel	2 (5)
Irinotecan	8 (20)
Ramucirumab/paclitaxel	11 (28)
Pembrolizumab	1 (2.5)
Nivolumab	1 (2.5)
Durvalumab/Tremelimumab	1 (2.5)
Best response to third-line treatment, n (%)
Complete response	1 (2.5)
Partial response	7 (18)
Stable disease	6 (15)
Progressive disease	25 (63)
Unknown	1 (2.5)
Median duration of third-line treatment (mo)	1.9 (0.9-4.4)
Reason for discontinuation of third-line treatment, n (%)
Progression	34 (85)
Toxicity	0
Other	3 (8)
Unknown	3 (8)
Fourth-line chemotherapy backbone [n = 6, n (%)]
5-FU	1 (17)
5-FU/oxaliplatin	2 (33)
5-FU/irinotecan	1 (17)
5-FU/cisplatin	1 (17)
Nivolumab	1 (17)
Best response to fourth-line treatment, n (%)
Complete response	0
Partial response	0
Stable disease	1 (17)
Progressive disease	5 (83)
Median duration of fourth-line treatment (mo)	2.57 (2.08-3.75)
Reason for discontinuation of fourth-line treatment, n (%)
Progression	6 (100)
Toxicity	0
Other	0
Unknown	0

5-FU: 5-fluorouracil.